开发一种新的CD26向化学抗原受体T细胞疗法,用于CD26表达T细胞恶性瘤
Eiji Kobayashi1, Yusuke Kamihara2, Miho Arai3
1Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Cells
|August 26, 2023
概括
第三代仿真抗原受体 (CAR) 针对CD26的T细胞疗法对T细胞恶性瘤具有前景. 这种先进的CAR T细胞疗法在临床前模型中有效抑制了瘤生长,提供了潜在的新治疗途径.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体 (CAR) T细胞疗法已用于B细胞恶性瘤.
- 针对T细胞恶性瘤的CAR T细胞疗法仍未得到充分发展.
- CD26是T细胞恶性瘤的潜在治疗标.
研究的目的:
- 开发和评估针对T细胞恶性瘤的针对CD26的CAR T细胞 (CD26-2G/3G).
- 评估第二代 (2G) 和第三代 (3G) CAR T细胞的疗效和安全性.
- 在临床前模型中研究针对CD26的CAR T细胞的治疗潜力.
主要方法:
- 使用人性化的单克隆抗体YS110.0.生成2G和3GCD26向的CAR T细胞.
- 在体外评估了CAR T细胞激活标记物 (CD69) 和细胞因子分泌物 (IFNγ).
- 在试验室中使用细胞系和患者衍生细胞评估了抗白血病和抗淋巴瘤作用.
- 在T细胞淋巴瘤和白血病的小鼠模型中进行了体内疗效测试.
主要成果:
- CD26-2G/3G CAR T细胞在与CD26+细胞共同培养时显示激活和分泌IFNγ.
- 试验室研究表明,对HSB2细胞具有显著的抗白血病作用,3G优于2G.
- CD26-2G/3G CAR T细胞对来自患者的T细胞淋巴瘤细胞有效.
- 在体内,CD26-3G CAR T细胞抑制了瘤生长,并在全身和皮下模型中改善了生存率,表现优于2G.
结论:
- 第三代CD26向的CAR T细胞疗法对T细胞恶性瘤具有显著的临床前疗效.
- 与2G CAR T细胞相比,CD26-3G CAR T细胞在体内表现出优越的抗瘤活性.
- 这种疗法代表了对T细胞恶性瘤的有希望的新治疗策略.
更多相关视频
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
645
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
相关概念视频
Tumor Immunotherapy
556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
T Cell Activation and Clonal Selection
806
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
806
